Bifemelane

Bifemelane is a benzylphenoxy alkylamine that Japanese pharmacology of the 1980s filed under the loose heading of "cerebral activator" or "cerebral metabolic enhancer," a category that also held indeloxazine, propentofylline, idebenone and the racetams. Its best-characterised molecular action is inhibition of monoamine oxidase. In human brain synaptosomes it inhibited MAO-A competitively (Ki about 4.2 micromolar) and MAO-B noncompetitively (Ki about 46 micromolar), and the inhibition reversed on dialysis, which places it among the reversible MAO-A inhibitors rather than the older irreversible agents ^[1]. That reversibility matters for its safety framing; the classic dietary and drug interaction hazards of MAO inhibition are tied largely to irreversible blockade.

On top of the MAO effect, animal work reads its antidepressant-like activity as an enhancement of noradrenergic transmission ^[2]. In the forced swim and reserpine models it behaved like a modest antidepressant, less potent than the reference agents it was tested against ^[2].

The second thread of its pharmacology is cholinergic. In aged rats subjected to chronic cerebral hypoperfusion, bifemelane raised choline acetyltransferase activity across cortex, hippocampus and striatum and increased muscarinic receptor binding ^[3]. In gerbils it softened the abnormal remodelling of hippocampal cholinergic markers after ischemia ^[4], and in rats with lesions of the nucleus basalis magnocellularis it restored cortical choline acetyltransferase activity and normalised the P300 event-related potential ^[5]. This cholinergic angle is the main reason it was studied in dementia and, in one small controlled study, in the naming deficits of aphasia ^[10].

Human data are thin and mostly Japanese. An open study in 13 patients with post-infarction depression reported that 150 mg per day for three months lowered Hamilton depression scores and shifted plasma noradrenergic and neuropeptide Y markers ^[6]. In 52 elderly depressed patients an 8 week course of 50 mg three times daily produced a global improvement rating around 80 percent with no reported side effects ^[7]. A placebo-controlled, double-blind crossover study in older subjects with cerebrovascular disorders found only a modest, non-significant increase in central activation measured by pupillary oscillation ^[8]. A comparative glaucoma study reported that 150 mg per day over 48 months preserved or improved the visual field in 70 percent of treated patients versus 20 percent of controls ^[9]. None of these are large modern trials.A supporting body of preclinical work credits bifemelane with neuroprotective and antioxidant properties: it blocked N-type and Q-type voltage-gated calcium channels that gate neurotransmitter release ^[11], reduced the ischemia-induced loss of hippocampal long-term potentiation in vivo ^[12], and protected cultured neurons against hydrogen peroxide by limiting lipid peroxidation ^[13]. Reviews of cognitive enhancers noted that it augmented mossy fiber long-term potentiation in hippocampal slices ^[14]. These are cell and animal findings, not clinical endpoints.

Bifemelane was discontinued in Japan in 1998. Its exit was not an isolated event; through the 1990s Japanese regulators re-examined the cerebral circulation and metabolism enhancers that had been widely prescribed after stroke, and a series of them failed to demonstrate durable efficacy in controlled re-evaluation and were withdrawn. Bifemelane fell in that wave. Today it is of historical and chemical interest more than clinical interest; its atomic structure was solved for the first time only in 2024 by microcrystal electron diffraction, long after it had left pharmacy shelves.

Human safety information is limited to small Japanese trials from the 1980s and 1990s, several of which reported no notable side effects over 8 weeks to several months of dosing at 150 mg per day ^[7][9]. Because bifemelane inhibits MAO-A, there is a theoretical concern for tyramine (the so-called cheese reaction) and for serotonergic interactions, but this risk is generally lower for reversible MAO-A inhibitors than for the older irreversible agents, and no such events were highlighted in the accessible clinical reports. Plasma concentrations varied widely between patients in a monitoring study, which complicates dose prediction ^[6]. Long-term safety, use in pregnancy, and interactions with modern serotonergic drugs are not well characterised. The drug was withdrawn for lack of proven efficacy rather than for a specific safety signal.

Bifemelane was developed in Japan under the code name MCI-2016 and marketed as Alnert and Celeport. It reached the market in the late 1980s as a cerebral activator and antidepressant, indicated chiefly for the depressive mood and reduced motivation seen in patients after cerebral infarction, and it was investigated in dementia, aphasia and glaucoma. Its MAO-inhibiting property was formally described in 1988 ^[1]. Through the 1990s, Japanese authorities re-evaluated the large family of cerebral circulation and metabolism enhancers that had been prescribed heavily after stroke; when controlled re-assessment failed to confirm durable benefit for many of them, they were removed from the market. Bifemelane was withdrawn in Japan in 1998, reportedly for lack of effectiveness. It was never approved in the United States or Europe.

Within pharmacology, bifemelane is remembered as a representative of the 1980s Japanese cerebral activator class, a group whose collective decline is often cited as a cautionary tale about approving nootropic and post-stroke agents on soft endpoints. It is not a compound with a meaningful modern following among nootropics users; it is obscure, off-market for over two decades, and hard to obtain, so real-world user experience is essentially absent. Interest today is mostly academic, whether as a reversible MAO-A inhibitor scaffold, a cholinergic and calcium-channel modulator, or, more recently, a test case for solving small-molecule drug structures by electron diffraction. Claims that it is a proven memory drug overstate what small, mostly uncontrolled trials actually showed.